Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Medicare covers sleep tests if you experience clinical signs and symptoms of sleep apnea, narcolepsy, or parasomnia. But there are some limitations depending on what condition is being screened for.

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

During the quarter, Lilly said it won approval in the U.S. for the use of Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity. Sales of the drug jumped to $1.9 ...

Additionally, researchers are exploring the possible role of medications in treating sleep apnea. One recent example is tirzepatide (Zepbound), a weight loss injection that was approved by the ...

Medicare covers sleep tests for certain conditions such as sleep apnea, narcolepsy, or parasomnia, but limitations may apply.

The drugmaker could also explain how it plans to promote Zepbound to older Americans covered by Medicare ... cover the drug as a treatment for sleep apnea, they said. Zepbound is expected to ...